CLINICAL ROLE -
Ivosidenib for Relapsed/Refractory Acute Myeloid Leukemia
On July 20, 2018, the FDA approved ivosidenib (Tibsovo) as a treatment option for adult patients with relapsed/refractory acute myeloid leukemia, specifically with a mutation in the IDH1 gene.
Nivestym by Pizer, Inc
On July 20, 2018, Pfizer Inc announced the FDA approval of filgrastim-aafi (Nivestym), a biosimilar to Amgenâ€™s biologic Neupogen (filgrastim).
Specialty Pharmacy Accreditations: The Big Three
Accreditation helps pharmaceutical manufacturers narrow the potential pharmacies it may include in a specialty network offering.
Revlimid for Multiple Myeloma
Celgene Corporationâ€™s lenalidomide (Revlimid) is a targeted therapy that stops the growth of myeloma cells in the bone marrow.
The Benefits of REMS Standardization and Multidimensional Communication Health Care Systems
With this technology interface, the health care system could experience enhanced communication, efficiency, and regulatory compliance, which makes patient safety the ultimate benefit.
2 Commerce Drive Cranbury, NJ 08512